Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid: a Multicenter Retrosepctive Study
Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This study was designed to be a retrospective, multicentre, observational study to evaluate the efficacy and safety of dupilumab in the treatment of bullous pemphigoid and to find predictors of efficacy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adult bullous pemphigoid patients treated with dupilumab between January 1, 2021, and July 31, 2022, at six leading dermatology departments in the Chinese Collaborative Network for Autoimmune Bullous Diseases.
• The diagnosis of BP requires clinical manifestations and immunological or pathological evidences.
• Dupilumab treatment should continue for at least 4 weeks and possibly longer.
Locations
Other Locations
China
Peking University First Hospital
Beijing
Time Frame
Start Date: 2022-09-01
Completion Date: 2023-01-31
Participants
Target number of participants: 146
Related Therapeutic Areas
Sponsors
Collaborators: Chinese Academy of Medical Sciences, Ruijin Hospital, West China Hospital, Second Xiangya Hospital of Central South University, Shandong Provincial Institute of Dermatology and Venereology
Leads: Peking University First Hospital